Abstract
Background Chemokine C-C motif ligand (CCL)21 and CCL19 are well-recognized to associate with adverse events of cardiovascular disease, especially long-term prognosis. However, few studies have reported its correlation with heart failure.
Purpose To investigate and compare the predictive value of CCL21 and CCL19 serum levels in patients with heart failure.
Methods In this prospective, observational, single-center study, 221 patients with heart failure and 55 healthy controls were included. ROC curves were generated to analyze and compare the serum levels of CCL21 and CCL19 in predicting all-cause mortality and composite events. Cox regression and Kaplan-Meier survival analyses were performed to identify independent risk factors for prognosis. Pearson correlation was used to measure the correlation between creatinine and CCL21 / CCL19 levels.
Results The study observed 108 events (30 deaths and 78 occurred composite endpoints) over a median follow-up of 494.5(231.5,950.0) days. CCL21 showed strong predictive value for both all-cause mortality (AUC were 0.694, P=0.001) and composite endpoints (AUC 0.661, P=0.006 and <0.001). while the combination of CCL21 and NT-proBNP further improved the predictive power, with AUC being 0.796 and 0.662 on all-cause mortality and composite endpoints, respectively (both P<0.001). K-M survival analysis revealed that patients with increased CCL21 and CCL19 exhibited higher all-cause mortality (both P<0.05). Meanwhile, higher incidence of composite endpoint events was also observed in patients with elevated CCL21 (P<0.05). Importantly, multivariate COX regression analysis demonstrated that smoking, higher level of CCL21 and ischemic heart disease were independent risk factors for all-cause mortality (P<0.001). Furthermore, diabetes and elevation of CCL21 were associated with an increased risk of composite endpoints (P<0.001). On the other hand, changes in CCL19 levels showed a graded association with worse renal function, resulting in a slight increasing trend in G3 and G4/5, (HR = 2.64, 95% CI= 2.26-2.66, vs. HR 2.67, 95% CI 2.57-2.91, overall interaction P<0.05), with higher concentrations in G3 and G4/5(HR = 3.67, 95% CI= 3.27-3.85, vs. HR 4.11, 95% CI 3.67-4.38; overall interaction P<0.05).
Conclusions Serum concentrations of CCL21 and CCL19 were significantly elevated in heart failure patients. High level of CCL21 is an independent risk factor for the adverse events in heart failure and may complement the prediction of those events which are less affected by renal function.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
K2019-05-032 K2021-01-031
Funding Statement
This work was supported by the National Natural Science Foundation of China (No. 81873515), Natural Science Foundation of Fujian (No. 2020J011072), Medical Innovation Project of Fujian Province, China (Grant No. 2021CXA008) and high-level hospital foster grants from Fujian Provincial Hospital, Fujian province, China (No. 2020HSJJ03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Helsinki Declaration and approved by the ethics committee of Fujian Provincial Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used to support the findings of this study are included within the article.
